Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases
Journal of Neurochemistry | September 20, 2018
Brinkmalm A, Portelius E, Brinkmalm G, Pannee J, Dahlen R, Gobom J, Blennow K and Zetterberg H J Neurochem. 2018 Sep 20. DOI: 10.1111/jnc.14594 ABSTRACT
Simoa assays are designed for the HD-1 Analyzer and the SR-X Ultra-Sensitive Biomarker Detection System to provide researchers ultra-sensitive analysis of protein concentration with the high precision and performance required to meet the needs of discovery and pre-clinical research.
The Quanterix SR-X is the latest instrument powered by Simoa® technology offering researchers access to ultra-sensitive biomarker detection capabilities in a compact affordable system.
The Simoa HD-1 Analyzer™ is a fully automated instrument for running immunoassays using Quanterix’ proprietary single molecule array, or Simoa, platform.
Blood Will Tell
The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, will transform the way brain injuries and diseases are diagnosed. Learn more about how the Simoa Platform can advance your CNS biomarker detection!
Simoa assays can detect biomarkers associated with brain injury and disease at much earlier stages to understand the long term effects and disease pathology.
The Quanterix Accelerator Laboratory is a dedicated laboratory environment for digitized biomarker research, custom assay development, and clinical sample testing using our Simoa™ technology.
The Simoa p24 Antigen Assay is an ultra-sensitive digital immunoassay providing 1,000 times improvement in detection limits compared with a traditional ELISA. The method can be used to detect early reactivation of infectious virus from latent reservoirs and determine efficacy of drugs and therap